Application of Dienogest In the Treatment of Endometriosis

Yuguang Chen, Ge Yang, Yining Zhao
In: Highlights in Science, Engineering and Technology · 2022 · vol. 8 , pp. 69–73 · doi:10.54097/hset.v8i.1112 · W4293001010
article OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

Dienogest, a progesterone derivative with anti-androgenic effects, effectively treats endometriosis by inhibiting ovarian function, reducing estrogen, and exerting anti-inflammatory and anti-angiogenic actions, though long-term follow-up is necessary.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-13 · read from full text ⓘ

This paper describes the progesterone agent dienogest as a therapeutic option for endometriosis, focusing on how it may reduce inflammatory and angiogenic processes driving endometrial-like lesions. It outlines dienogest’s proposed mechanisms, including inhibition of the hypothalamus–pituitary–ovarian axis, reduction of estrogen metabolic enzyme activity to lower estrogen levels, and downstream effects on pain and lesion development, with outcomes noted such as reduced ovarian endometrioma cysts, pain relief, and decreased recurrence. The paper also acknowledges that uterine bleeding can occur and states that careful long-term follow-up is required, but it does not provide detailed study design, population, or quantitative results within the excerpt. This paper is centrally about endometriosis — it discusses dienogest’s mechanisms and effects on endometriosis-related pain, ovarian endometriomas, and recurrence.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a condition that exists endometrioid epithelium and/or endometrialmatrix muscular layer,usually accompanied by inflammatory processes.The new progesterone,Dienogest (DNG),has no estrogen,anti-estrogen and androgen activities,at the same time,DNGhas anti androgen activity.With a favorable safety and tolerability profile,DNG could relief pain and reduce ovarian endometriosis cysts,reduces the recurrence,meanwhile,DNG also has good effect on recurrent endometriosis.DNG mainly mediates the hypothalamus,pituitary and ovarian axis to inhibit the functions of ovarian.It can also inhibit the synthesis of estrogen metabolic enzymes,to reduce estrogen level.Through anti-inflammation and anti-angiogenesis,DNG could inhibit the development of pain,inhibite the occurrence and development of EMT lesions,which can be used as medicine for long-term management of endometriosis.Side effects such as uterine bleeding was observed,inform the patient in advance of compliance,careful long-term follow-up is required.
Full text 5,417 characters · extracted from oa-doi-fallback · click to expand
Application of Dienogest In the Treatment of Endometriosis DOI: https://doi.org/10.54097/hset.v8i.1112Keywords: Endometriosis, Dienogest, Pain, Cyst, Recurrence.Abstract Endometriosis is a condition that exists endometrioid epithelium and/or endometrialmatrix muscular layer,usually accompanied by inflammatory processes.The new progesterone,Dienogest (DNG),has no estrogen,anti-estrogen and androgen activities,at the same time,DNGhas anti androgen activity.With a favorable safety and tolerability profile,DNG could relief pain and reduce ovarian endometriosis cysts,reduces the recurrence,meanwhile,DNG also has good effect on recurrent endometriosis.DNG mainly mediates the hypothalamus,pituitary and ovarian axis to inhibit the functions of ovarian.It can also inhibit the synthesis of estrogen metabolic enzymes,to reduce estrogen level.Through anti-inflammation and anti-angiogenesis,DNG could inhibit the development of pain,inhibite the occurrence and development of EMT lesions,which can be used as medicine for long-term management of endometriosis.Side effects such as uterine bleeding was observed,inform the patient in advance of compliance,careful long-term follow-up is required. Downloads References Berkley, Karen J, Rapkin, Andrea J, and Papka, Raymond E. “The Pains of Endometriosis.” Science (American Association for the Advancement of Science) 308.5728 (2005): 1587–1589. Web. Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations[J]. Lancet, 2021, 397(10276): 839-852. DOI: 10.1016/S0140-6736(21)00389-5. Muzii L, Galati G, Di Tucci C, et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain[J]. Gynecol Endocrinol, 2020,36(1):81-83. Harada, Tasuku, and Taniguchi, Fuminori. “Dienogest: a New Therapeutic Agent for the Treatment of Endometriosis.” Women's health (London, England) 6.1 (2010): 27–35. Web. Koshiba A, Mori T, Okimura H, et al. Dienogest therapy duringthe early stages of recurrence of endometrioma might be an alter-native therapeutic option to Dynamic observation and observation [J]. J obstetrop obstetrop, 2018,44 (10) : 1970-1976. Sutton, C. J. G., and Jones, Kevin. Endometriosis. N.p.Chapter2 pp.9-16, 2004. Print. Yamanaka A, Hada T, Matsumoto T, et al. Effect of dienogest onpain and ovarian endometrioma occurrence after laparoscopic resec-tion of uterosacral ligaments Weight loss and weight loss in endometriosis patients [J]. Eur J Obstet Gynecol Reprod Biol, 2017, 216:51-55. Qiu. Jin, Xu. Han, (2021), Clinical progress of Dienogest in the treatment of endometriosis Hayashi. A, Tanabe A, Kawabe S, et al. (2012), Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. Nirgianakis K, Grandi G, McKinnon B, et al. (2016), Dienogest mediates midkine suppression in endometriosis. Angioni S, Pontis A, Malune ME, et al. Is dienogest the best medical treatment for ovarian endometriomas?Results of a multicentric case control study[J]. Gynecol Endocrinol，2020， 36（1）： 84-86. Del Forno S, Mabrouk M, Arena A, et al. Dienogest or Norethindrone acetate for the treatment of ovarian endometriomas：Can we avoid surgery?[J]. Eur J Obstet Gynecol Reprod Biol,2019,238： 120-124. Lili. Duan, Zhibin. Li, et al, (2021), Effect of Dienogest in the treatment of endometriosis Fu L, Osuga Y, Morimoto C, et al. Dienogest inhibits BrdU uptake with G0 ／ G1 arrest in cultured endometriotic stromal cells [J]. Fertil Steril,2008,89（5 Suppl）：1344-1347. Ono YJ, Terai Y, Tanabe A, et al. Suppression of endometriosis by progester-one Plays a crucial role in suppressing endometriosis [J]. J endo-crinol, 2014,223 (2) : 203-216. Sutton, C. J. G., and Jones, Kevin. Endometriosis. N.p.Chapter5 pp. 37-60, 2004. Print. Ozaki R, Kumakiri J, Jinushi M, et al. Comparison of effect ofpreoperative dienogest and gonadotropin-releasing hormone ago-nist administration on laparoscopic Cystectomy for ovarian endome-triomas [J]. Arch Gynecol Obstet, 2020,302 (4) : 969-976. Sugimoto K, Nagata C, Hayashi H, et al. Use of dienogest over53weeks in the treatment of endometriosis [J]. J Obstet GynaecolRes, 2016,41 (12) : 1921-1926. Koshiba A, Mori T, Okimura H, et al. Dienogest therapy duringthe early stages of recurrence of endometrioma might be an alter-native therapeutic option to Dynamic observation and observation [J]. J obstetrop obstetrop, 2018,44 (10) : 1970-1976. Leonardo Pinto JP, Benetti Pinto CL, Cursino K, Et al. Dienogestand deep infiltrating endometriosis: Observation of symptoms of endometriosis nodule patients and their weight loss rate [J]. Eur J Obstetroobstetrope TGynecol Reprod Biol, 2017, 211:108-111. Yamanaka A, Hada T, Matsumoto T, et al. Effect of dienogest onpain and ovarian endometrioma occurrence after laparoscopic resec-tion of uterosacral ligaments Weight loss and weight loss in endometriosis patients [J]. Eur J Obstet Gynecol Reprod Biol, 2017, 216:51-55. Lang J, Yu Q, Zhang S, Li H, Gude K, von Ludwig C, Ren X, Dong L. Dienogest for Treatment of Endometriosis in Chinese Women: A Placebo-Controlled, Randomized, Double-Blind Phase 3 Study. J Womens Health (Larchmt). 2018 Feb;27(2):148-155. Downloads Published Issue Section License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK